Ushaka Wenqwaba

-Delile

• Cishe ayisebenzi ku ...
• Ubufakazi obanele bokukala ukusebenza kwe ...
• Ukuqapha okukhethekile nezixwayiso:

Ushaka uqwanga (izicubu ezinzima ezinwebeka ezinikeza ukusekelwa, njengoba kwenza ithambo) ezisetshenziselwa umuthi zivela ikakhulu koshaka ababanjwe oLwandlekazi iPacific. Izinhlobo eziningi zokukhishwa zenziwe ngoqwanga lukashaka kufaka phakathi i-squalamine lactate, i-AE-941, ne-U-995.

Uqwanga lukaShaka lusetshenziswa kakhulu emdlalweni womdlavuza. Ushaka we-Shark isetshenziselwa i-osteoarthritis, i-plaque psoriasis, ukulahleka kombono okuhlobene nobudala, ukuphulukiswa kwesilonda, ukulimala kwe-retina yeso ngenxa yesifo sikashukela, nokuvuvukala kwamathumbu (i-enteritis).

Abanye abantu basebenzisa uqwanga lukashaka ngqo esikhumbeni se-arthritis ne-psoriasis.

Abanye abantu basebenzisa uqwanga lukashaka ku-rectum yomdlavuza.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze USHAKA WAKWA-SHARK zimi kanje:

Cishe ayisebenzi ku ...

• Umdlavuza. Ucwaningo oluningi lukhombisa ukuthi ukuthatha uqwanga lukashaka ngomlomo akubazuzisi abantu abanomdlavuza osezingeni eliphezulu, owake waphathwa ngaphambilini webele, ikholoni, iphaphu, indlala yesinye, noma ubuchopho. Futhi akubonakali kuzuzisa abantu abane-lymphoma esezingeni eliphezulu, eyayiphethwe phambilini engeyona iHodgkin's lymphoma. Uqwanga lukashaka alukaze lucwaningwe kubantu abanomdlavuza ongaphakeme kangako.

Ubufakazi obanele bokukala ukusebenza kwe ...

• Isimila somdlavuza esibizwa ngeKaposi sarcoma. Kunemibiko yokuthi ukusebenzisa uqwanga lukashaka esikhunjeni kunganciphisa izicubu ezibizwa ngeKaposi sarcoma. Lezi zicubu zivame kakhulu kubantu abane-HIV.
• I-osteoarthritis. Lapho isetshenziswa esikhumbeni, imikhiqizo equkethe uqwanga lukashaka ngokuhlangana nezinye izithako kubikwa ukuthi yehlisa izimpawu zesifo samathambo. Kodwa-ke, noma yikuphi ukukhululeka kwezimpawu kungenzeka kakhulu kungenxa yesithako se-camphor hhayi ezinye izithako. Ngokwengeziwe, alukho ucwaningo olukhombisa ukuthi uqwanga lukashaka lumuncwa ngesikhumba.
• I-Psoriasis. Ucwaningo olwenziwe kusenesikhathi kubantu abane-plaque psoriasis lukhombisa ukuthi ukukhishwa koshaka othile oshaka (AE-941) kuthuthukisa ukubukeka kwamapuleti futhi kunciphise ukulunywa lapho kuthathwa ngomlomo noma kusetshenziswa esikhumbeni.
• Uhlobo lomdlavuza wezinso obizwa nge-renal cell carcinoma. Ukuthatha i-shark cartilage cartilage ethile (AE-941) ngomlomo kungakhuphula ukusinda ezigulini ezine-renal cell carcinoma.
• Ukulahleka kombono okuhlobene nobudala.
• Ukuphulukiswa kwesilonda.
• Ezinye izimo.

Kudingeka ubufakazi obengeziwe ukukala uqwanga lukashaka kulokhu kusetshenziswa.

Uqwanga lukaShark lungavimbela ukukhula kwemithambo yegazi emisha edingekayo ukuze umdlavuza ukhule. Kungavimbela nokukhula kwemithambo yegazi kwizilonda ze-psoriasis. Lokhu kungasiza ukupholisa la manxeba.

Uqwanga lukashaka OKUNGENZEKA UKUPHEPHA kubantu abaningi lapho bethathwe ngomlomo izinyanga ezifika kwezingama-40 noma lapho befakwa esikhumbeni kuze kube amasonto ayi-8.

Kungadala ukunambitheka okubi emlonyeni, isicanucanu, ukuhlanza, ukucasuka kwesisu, ukuqunjelwa, umfutho ophansi wegazi, isiyezi, ushukela ophakeme wegazi, amazinga aphezulu e-calcium, ubuthakathaka nokukhathala. Kungadala nokungasebenzi kwesibindi. Eminye imikhiqizo inephunga nokunambitheka okungathandeki.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibele: Alukho ulwazi olwanele ngokwanele mayelana nokuphepha kokuthatha uqwanga lukashaka uma ukhulelwe noma uncelisa ibele. Hlala ohlangothini oluphephile futhi ugweme ukusetshenziswa.

"Izifo ezizimele" njenge-multiple sclerosis (MS), lupus (systemic lupus erythematosus, SLE), isifo samathambo (RA), noma ezinye izimo: Uqwanga lukashaka lungadala ukuthi amasosha omzimba asebenze kakhudlwana. Lokhu kungakhuphula izimpawu zezifo ezizimele. Uma unenye yalezi zimo, kungcono ukugweme ukusebenzisa uqwanga lukashaka.

Amazinga aphezulu e-calcium (hypercalcemia)I-Shark cartilage ingakhuphula amazinga e-calcium, ngakho-ke akufanele isetshenziswe abantu abanamazinga e-calcium asevele esephezulu kakhulu.

Maphakathi

Qaphela ngale nhlanganisela.

Imithi eyehlisa amasosha omzimba (ama-Immunosuppressants)

Uqwanga lukashaka lungakhuphula amasosha omzimba. Ngokwandisa amasosha omzimba, u-shark cartilage anganciphisa ukusebenza kwemithi eyehlisa amasosha omzimba.

Eminye imishanguzo eyehlisa amasosha omzimba ifaka i-azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf ), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), nabanye.

I-calcium

Uqwanga lukashaka lungakhuphula amazinga e-calcium. Kukhona ukukhathazeka ukuthi ukuyisebenzisa kanye nezithako ze-calcium kungenza amazinga e-calcium abe phezulu kakhulu.

Isiphuzo sezithelo

Ijusi yezithelo ene-asidi efana ne-orange, i-apula, amagilebhisi, noma utamatisi, ingehlisa amandla e-shark cartilage njengoba imizuzu idlula. Uma u-shark cartilage engezwa kujusi wezithelo, kufanele wengezwe ngaphambi nje kokusetshenziswa.

Umthamo ofanele woqwanga lukashaka uncike ezicini eziningana ezifana nobudala bomsebenzisi, impilo, kanye nezinye izimo eziningana. Ngalesi sikhathi alukho ulwazi olwanele lwesayensi lokunquma ububanzi obufanele bemithamo ye-shark cartilage. Khumbula ukuthi imikhiqizo yemvelo ayihlali iphephile njalo futhi imithamo ingabaluleka. Qiniseka ukuthi ulandela izinkomba ezifanele kumalebula womkhiqizo futhi uthintane nosokhemisi wakho noma udokotela noma omunye uchwepheshe wezokunakekelwa kwempilo ngaphambi kokusebenzisa.

AE-941, Cartilage de Requin, Cartilage de Requin du Pacifique, Cartilago de Tiburon, Collagène Marin, Extrait de Cartilage de Requin, Liquide de Cartilage Marin, Marine Collagen, Marine Liquid Cartilage, MSI-1256F, Neovastat, Pacific Shark Cartilage, Poudre de Cartilage de Requin, Shark Cartilage Powder, Shark Cartilage Extract, Sphyrna lewini, Squalus acanthias.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.

1. UMerly L, uSmith SL. Izici ezi-pro-inflammatory zeshaka ye-shark cartilage. I-Immunopharmacol I-Immunotoxicol. 2015; 37: 140-7. Buka okungaqondakali.
2. Sakai S, Otake E, Toida T, Goda Y. Ukukhonjwa kwemvelaphi ye-chondroitin sulfate "ekudleni kwezempilo". UChem Pharm Bull (eTokyo). 2007; 55: 299-303. Buka okungaqondakali.
3. IBhodi Yokuhlela Yezindlela Zokuhlanganisa, Ezihlukile, Futhi Ezihambisanayo Zokwelashwa. Uqwanga (Bovine and Shark) (PDQ®): Health Professional Version. Izifinyezo Zolwazi Lomdlavuza we-PDQ [i-Intanethi]. I-Bethesda (MD): I-National Cancer Institute (i-US); 2002. 2016 Jul 21. View abstract.
4. UGoldman E. Shark uqwanga ekhishwe wazama njengokwelashwa kwe-psoriasis yenoveli. Isikhumba Zonke Izindaba 1998; 29: 14.
5. Ukuphathwa Kwezokudla Nezidakamizwa. I-FDA ithatha isinyathelo ngokuthengisa ngokuqinile izidakamizwa ezingagunyaziwe. Iphepha lokukhuluma le-FDA (Disemba 10, 1999)
6. ULane W noMilner M. Ukuqhathanisa uqwanga lukashaka kanye noqwanga lwezinkomo. I-Townsend Lett 1996; 153: 40-42.
7. UZhuang, L, Wang, B, Shivji, G, no-al. I-AE-941, i-inhibitor yenoveli ye-angiogenesis inethonya elibalulekile lokulwa nokuvuvukala ku-hypersensitivity yokuxhumana. J Invest Derm 1997; 108: 633.
8. I-Turcotte P. Phase I isifundo sokukhuphuka kwesilinganiso se-AE-941, i-ejenti ye-antiangiogenic, esigulini esiwohlokayo esihlobene nobudala. Ingqungquthela yeRetina Society (eHawaii, Disemba 2, 1999).
9. I-Saunder DN. Umphikisi we-Angiogenesis njengokwelashwa kwe-psoriasis: Isigaba I imiphumela yokuhlolwa komtholampilo nge-AE-941. I-American Academy of Dermatology Conference, eNew Orleans, eLouisiana, ngoMashi 19-24, 1999.
10. I-Aeterna Laboratories Inc. Isigaba III sokuhlola okungahleliwe kwe-AE-941 (Neovastat; Shark Cartilage Extract) ezigulini ezine-metastatic renal cell carcinoma refractory to immunotherapy. 2001.
11. U-Escudier, B, Patenaude, F, Bukowski, R, no-al. Isizathu sesivivinyo somtholampilo sesigaba III nge-AE-941 (Neovastat (R)) ezigulini ze-metastatic renal cell carcinoma eziphikisa i-immunotherapy. U-Ann Oncol 2000; 11 (engeza 4): 143-144.
12. UDupont E, Alaoui-Jamali M, Wang T, no-al. Umsebenzi we-Angiostatic and antitumoral we-AE-941 (Neovastat), ingxenyenamba yamangqamuzana ethathwe ku-shark cartilage. Izinqubo ze-American Association for Cancer Research 1997; 38: 227.
13. UShimizu-Suganuma, Masum, Mwanatambwe, Milanga, Iida, Kazum, et al. Umphumela woqwanga lukashaka ekukhuleni kwesimila nesikhathi sokusinda e-vivo (meeting abstract). I-Proc Annu Hlangana ne-Am Clin Clin Oncol 1999; 18: A1760.
14. Ongaziwa. Umsebenzi we-Angiostatic ne-antitumoral we-AE-941 (neovastat-R), ingxenyenamba yamangqamuzana ethathwe ku-shark cartilage (meeting abstract). I-Proc Annu Hlangana ne-Am Assoc Cancer Res 1997; 38: A1530.
15. UCataldi, JM no-Osborne, DL. Imiphumela ye-shark cartilage ku-mammary tumor neovascularization ku-vivo nokwanda kweseli in vitro (meeting abstract). Ijenali yeFASEB 1995; 9: A135.
16. UJamali MA, uRiviere P, uFalardeau A, no-al. Umphumela we-AE-941 (Neovastat), i-angiogenesis inhibitor, ku-Lewis lung carcinoma metastatic model, ukusebenza kahle, ukuvimbela ubuthi nokusinda. I-Clin Invest Med 1998; (suppl): S16.
17. I-Saad F, i-Klotz L, i-Babaian R, i-Lacombe L, i-Champagne P, ne-Dupont E. Isigaba se-I / II esivivinywa ku-AE-941 (Neovastat) ezigulini ezinomdlavuza we-prostate we-metastatic refractory (isethulo esingabonakali). Umhlangano Wonyaka WeCanada Urological Association (Juni 24-27, 2001).
18. URosenbluth, RJ, Jennis, AA, Cantwell, S, no-al. I-Oral shark cartilage ekwelapheni iziguli ezinezicubu zobuchopho eziphambili ezithuthukile. Isifundo somshayeli wesigaba II (ukuhlangana okungabonakali). I-Proc Annu Hlangana ne-Am Soc Clin Oncol 1999; 18: A554.
19. UDupont E, uSavard RE, uJourdain C, uJuneau C, uThibodeau A, uRoss N, no-al. Izakhiwo ze-antiangiogenic zokukhishwa kwe-shark cartilage yenoveli: iqhaza elingaba khona ekwelapheni i-psoriasis. UJ Cutan Med Surg 1998; 2: 146-152.
20. I-Lane IW ne-Contreras E. Izinga eliphakeme le-bioactivity (ukwehla ngosayizi omningi we-tumor) kubonwe ezigulini zomdlavuza osezingeni eliphezulu eziphathwa ngezinto zoshaka. UJ Naturopath Med 1992; 3: 86-88.
21. UWilson JL. I-topical shark cartilage inqobe i-psoriasis. I-Altern Comp Ther 2000; 6: 291.
22. URiviere M, Latreille J, noFalardeau P. AE-941 (Neovastat), i-inhibitor ye-angiogenesis: imiphumela yokuhlolwa komdlavuza wesigaba I / II. ICancer Invest 1999; 17 (suppl 1): 16-17.
23. Milner M. Umhlahlandlela wokusetshenziswa koqwanga lukashaka ekwelapheni isifo samathambo nezinye izifo ezihlangene zokuvuvukala. I-Amer Chiropractor 1999; 21: 40-42.
24. ILeitner SP, iRothkopf MM, iHaverstick DD, kanye et al. Izifundo ezimbili zesigaba II somlomo owomile we-shark cartilage powder (i-SCP) ezigulini ezinesifuba se-metastatic noma umdlavuza we-prostate ophikisayo ekwelashweni okujwayelekile. I-Amer Soc Clin Oncol 1998; 17: A240.
25. U-Evans WK, Latreille J, Batist G, no-al. I-AE-941, i-inhibitor ye-angiogenesis: isizathu sokuthuthuka ngokuhlangana ne-induction chemotherapy / radiotherapy ezigulini ezinomdlavuza ongewona omncane wamangqamuzana wamaphaphu (NSCLC). Amaphepha Akhiqiziwe 1999; S250.
26. URiviere M, Falardeau P, Latreille J, no-al. Imiphumela yesivivinyo somdlavuza wesigaba se-I / II somdlavuza wamaphaphu nge-AE-941 (Neovastat ®) i-inhibitor ye-angiogenesis. I-Clin Invest Med (engeza) ngo-1998; i-S14.
27. URiviere M, Alaoui-Jamali M, Falardeau P, no-al. I-Neovastat: i-inhibitor ye-angiogenesis enomsebenzi wokulwa nomdlavuza. I-Proc Amer Assoc Cancer Res 1998; 39: 46.
28. Abekho ababhali. Izichasiselo zesilingo somtholampilo seNeovastat. 2001;
29. I-Aeterna Laboratories Inc. Ucwaningo lweSigaba II lwe-AE-941 (Neovastat; Shark Cartilage) ezigulini ezibuyela emuva kusenesikhathi noma i-myeloma eminingi ephikisayo. 2001. Inombolo Yokuxhumana Yolwazi 1-888-349-3232.
30. UFelzenszwalb, I., Pelielo de Mattos, J. C., Bernardo-Filho, M., noCaldeira-de-Araujo, A. Ukulungiselela okuqukethe uqwanga: ukuvikelwa ezinhlotsheni zomoya-mpilo ezisebenzayo. Ukudla Chem Toxicol 1998; 36: 1079-1084. Buka okungaqondakali.
31. ICoppes, M. J., Anderson, R. A., Egeler, R. M., noWolff, J. E. Ezinye izindlela zokwelapha umdlavuza wezingane. N Engl. J Med 9-17-1998; 339: 846-847. Buka okungaqondakali.
32. UDavis, P.F, He, Y., Furneaux, R.H, Johnston, P. S., Ruger, B. M., noSlim, G. C. Ukuvinjelwa kwe-angiogenesis ngokufaka ngomlomo uqwanga lukashaka oluyimpuphu kumodeli yegundane. IMicrosoftvasc. 1997; 54: 178-182. Buka okungaqondakali.
33. UMcGuire, T. R., Kazakoff, P. W., Hoie, E. B., noFienhold, M. A. Umsebenzi wokuvimbela u-cartilage oshaka ngaphandle kwe-tumor necrosis factor-alpha ku-veil endothelium ye-umbilical vein. I-Pharmacotherapy 1996; 16: 237-244. Buka okungaqondakali.
34. Kuettner, K. E. noPauli, B. U. Ukuvinjelwa kwe-neovascularization nge-cartilage factor. I-Ciba Itholakele. 1983; 100: 163-173.Buka okungaqondakali.
35. U-Lee, A. no-Langer, R. Shark uqwanga luqukethe ama-inhibitors we-tumor angiogenesis. Isayensi 9-16-1983; 221: 1185-1187. Buka okungaqondakali.
36. IKorman, D. B. [Izici ze-antiangiogenic kanye ne-antitumor of cartilage]. I-Vopr. I-Onkol. 2012; 58: 717-726. Buka okungaqondakali.
37. UPatra, D. noSandell, uL. J. Antiangiogenic kanye nama-anticancer molecule ku-cartilage. Isazi. Rev Mol.Med 2012; 14: e10. Buka okungaqondakali.
38. de Mejia, E. G. noDia, V. P. Indima yamaprotheni we-nutraceutical kanye nama-peptides ku-apoptosis, angiogenesis, kanye ne-metastasis yamaseli womdlavuza. I-Cancer Metastasis Rev 2010; 29: 511-528. Buka okungaqondakali.
39. Bargahi, A., Hassan, Z. M., Rabbani, A., Langroudi, L., Noori, S. H., noSafari, E. Umphumela we-shark cartilage etholakala amaprotheni emisebenzini yamaseli we-NK. I-Immunopharmacol.Immunotoxicol. 2011; 33: 403-409. Buka okungaqondakali.
40. U-Lee, S.Y. noChung, S. M. Neovastat (AE-941) uvimbela ukuvuvukala kwomoya ngokusebenzisa ukucindezelwa kwe-alpha ye-VEGF ne-HIF-2. IVascul. Pharmacol 2007; 47 (5-6): 313-318. Buka okungaqondakali.
41. UPearson, W., Orth, M. W., Karrow, N. A., Maclusky, N. J., noLindinger, M. I. Imiphumela yokulwa nokuvuvukala kanye ne-chondroprotective yama-nutraceuticals avela ku-Sasha's Blend kwimodeli yokuqhuma koqwanga. IMol Nutrut Res Res 2007; 51: 1020-1030. Buka okungaqondakali.
42. UKim, S., de, A., V, Bouajila, J., Dias, AG, Cyrino, FZ, Bouskela, E., Costa, PR, noNepveu, F. Alpha-phenyl-N-tert-butyl nitrone ( Okutholwayo yi-PBN): synthesis kanye nesenzo sokuzivikela kumonakalo we-microvascular obangelwa yi-ischemia / reperfusion. I-Bioorg. I-Med Chem 5-15-2007; 15: 3572-3578. Buka okungaqondakali.
43. UMerly, L., Simjee, S., noSmith, S. L. Ukukhishwa kwama-cytokines okuvuvukala ngokukhishwa kwe-cartilage. I-Immunopharmacol. 2007; 7: 383-391. Buka okungaqondakali.
44. UMoses, M. A., Sudhalter, J., noLanger, R. Ukukhonjwa kwe-inhibitor ye-neovascularization kusuka ku-cartilage. Isayensi 6-15-1990; 248: 1408-1410. Buka okungaqondakali.
45. URatel, D., Glazier, G., Provencal, M., Boivin, D., Beaulieu, E., Gingras, D., noBeliveau, R. Ama-enzyme e-fibrinolytic aqondisa ngqo ku-shark cartilage akhiphe: indima engaba khona yokwelapha emithanjeni iziyaluyalu. I-Thromb.Izimali. 2005; 115 (1-2): 143-152. Buka okungaqondakali.
46. UGingras, D., Labelle, D., Nyalendo, C., Boivin, D., Demeule, M., Barthomeuf, C., noBeliveau, R. Umenzeli we-antiangiogenic uNeovastat (AE-941) uvuselela umsebenzi wesishoshovu se-plasminogen. Tshala Izidakamizwa Ezintsha 2004; 22: 17-26. Buka okungaqondakali.
47. ILatreille, J., Batist, G., Laberge, F., Champagne, P., Croteau, D., Falardeau, P., Levinton, C., Hariton, C., Evans, WK, noDupont, E. Phase Isilingo se-I / II sokuphepha nokusebenza kwe-AE-941 (Neovastat) ekwelapheni umdlavuza wamaphaphu ongelona elincane. Umdlavuza we-Clin Lung 2003; 4: 231-236. Buka okungaqondakali.
48. I-Bukowski, R. M. AE-941, i-antiangiogenic composite: izilingo ku-renal cell carcinoma. Isazi.Opin.Investig.Izidakamizwa 2003; 12: 1403-1411. Buka okungaqondakali.
49. UJagannath, S., Champagne, P., Hariton, C., noDupont, E. Neovastat ku-myeloma eminingi. I-Eur. J. Haematol. 2003; 70: 267-268. Buka okungaqondakali.
50. I-FDA inika isimo sezintandane nesidakamizwa ku-Aeterna's Neovastat ngomdlavuza wezinso. Isazi. Rev Anticancer Ther 2002; 2: 618. Buka okungaqondakali.
51. UDupont, E., Falardeau, P., Mousa, SA, Dimitriadou, V., Pepin, MC, Wang, T., no-Alaoui-Jamali, MA Antiangiogenic kanye ne-antimetastatic izakhiwo zeNeovastat (AE-941), okukhishwa ngomlomo etholakala ku-cartilage tissue. I-Clin Exp Metastasis 2002; 19: 145-153. Buka okungaqondakali.
52. Beliveau, R., Gingras, D., Kruger, EA, Lamy, S., Sirois, P., Simard, B., Sirois, MG, Tranqui, L., Baffert, F., Beaulieu, E., Dimitriadou, V., Pepin, MC, Courjal, F., Ricard, I., Poyet, P., Falardeau, P., Figg, WD, noDupont, E. I-Antiangiogenic Agent Neovastat (AE-941) Ivimbela i-Vascular Endothelial Growth Factor. Imiphumela ye-Biological -mediated. I-Clin Cancer Res 2002; 8: 1242-1250. Buka okungaqondakali.
53. UWeber, M.H, Lee, J., no-Orr, F. W. Umphumela weNeovastat (AE-941) kwimodeli yesilingo se-metastatic bone tumor. I-Int J Oncol 2002; 20: 299-303. Buka okungaqondakali.
54. Barber, R., Delahunt, B., Grebe, S. K., Davis, P. F., Thornton, A., no-Slim, G. C. Oral shark cartilage ayiqedi i-carcinogenesis kepha ibambezela ukuqhubekela phambili kwesigaxa semodeli ye-murine. I-Anticancer Res 2001; 21 (2A): 1065-1069. Buka okungaqondakali.
55. IGonzalez, RP, Soares, FS, Farias, RF, Pessoa, C., Leyva, A., Barros Viana, GS, neMoraes, MO Ukuboniswa kwethonya lokuvimbela uqwanga lomlomo ku-fibroblast ukukhula factor-okubangelwa i-angiogenesis kunogwaja i-cornea. Biol.Pharm.Inkunzi. 2001; 24: 151-154. Buka okungaqondakali.
56. Brem, H. noFolkman, J. Ukuvinjelwa kwe-tumor angiogenesis okulamulelwe uqwanga. J Exp. Medied 2-1-1975; 141: 427-439. Buka okungaqondakali.
57. Koch, A. E. Indima ye-angiogenesis ku-rheumatoid arthritis: intuthuko yakamuva. U-Ann Rheum. 2000; 59 Suppl 1: i65-i71. Buka okungaqondakali.
58. Izinkulumo, K. L. noHarris, A. L. Isimo samanje sezici ze-antiangiogenic. UBr J Haematol. 2000; 109: 477-489. Buka okungaqondakali.
59. UMorris, G. M., Coderre, J. A., Micca, P. L., Lombardo, D.T, noHopewell, J. W. Boron neutron Capture therapy of the rat 9L gliosarcoma: assessment of the effects of shark cartilage. Br J Imisebe. 2000; 73: 429-434. Buka okungaqondakali.
60. URenckens, C.N no van Dam, F. S. [Isikhwama somdlavuza kuzwelonke (Koningin Wilhelmina Fonds) kanye ne-Houtsmuller-therapy yomdlavuza]. Ned.Tijdschr.Geneeskd. 7-3-1999; 143: 1431-1433. Buka okungaqondakali.
61. UMoses, MA, Wiederschain, D., Wu, I., Fernandez, CA, Ghazizadeh, V., Lane, WS, Flynn, E., Sytkowski, A., Tao, T., noLanger, R. Troponin ngingu ekhona kuqwanga lomuntu futhi ivimbela i-angiogenesis. I-Proc Natl.Acad.Sci.U.S. 3-16-1999; 96: 2645-2650. Buka okungaqondakali.
62. UMoller HJ, uMoller-Pedersen T, uDamsgaard TE, uPoulsen JH. Ukubonakaliswa kwe-immunogenic keratin sulphate ku-chondroitin yezentengiso 6-sulfate kusuka ku-shark cartilage. Imiphumela yezivivinyo ze-ELISA. Umtholampilo Chim Acta 1995; 236: 195-204. Buka okungaqondakali.
63. ULu C, uLee JJ, uKomaki R, et al. I-Chemoradiotherapy nge-AE-941 noma ngaphandle kwayo esigabeni III somdlavuza wamangqamuzana ongewona omncane: isilingo sesigaba III esingahleliwe. UJ Natl Cancer Inst 2010; 102: 1-7. Buka okungaqondakali.
64. ULoprinzi CL, uLevitt R, uBarton DL, et al. Ukuhlolisiswa koqwanga lukashaka ezigulini ezinomdlavuza osezingeni eliphakeme: isivivinyo seNyakatho yeCancer Treatment Group. Umdlavuza 2005; 104: 176-82. Buka okungaqondakali.
65. UBatist G, uPatenaude F, uChampagne P, et al. I-Neovastat (AE-941) ezigulini ze-renal cell carcinoma eziphikisayo: umbiko wesivivinyo sesigaba II ngamazinga womthamo amabili. U-Ann Oncol 2002; 13: 1259-63 .. Buka okungaqondakali.
66. USauder DN, uDekoven J, uChampagne P, et al. I-Neovastat (AE-941), i-inhibitor ye-angiogenesis: Isivivinyo somtholampilo esingahleliwe se-I / II siphumela kwiziguli ezine-plaque psoriasis. J Am Acad Dermatol 2002; 47: 535-41. Buka okungaqondakali.
67. UGingras D, uRenaud A, uMousseau N, et al. Ukuvinjelwa kweMatrix proteinase yi-AE-941, inhlanganisela esebenzayo ye-antiangiogenic. I-Anticancer Res 2001; 21: 145-55 .. Buka okungaqondakali.
68. UFalardeau P, uChampagne P, uPoyet P, et al. I-Neovastat, umuthi osebenza ngokwemvelo we-antiangiogenic, ezilingo zokwelashwa zesigaba III. USemin Oncol 2001; 28: 620-5 .. Buka okungaqondakali.
69. UBoivin D, uGendron S, Beaulieu E, et al. Umenzeli we-antiangiogenic Neovastat (AE-941) ukhuthaza i-endothelial cell apoptosis. I-Mol Cancer Ther 2002; 1: 795-802 .. Buka okungaqondakali.
70. UCohen M, uWolfe R, uMai T, uLewis D. Isivivinyo esilawulwa ngokungahleliwe, esiyimpumputhe kabili, se-placebo sokhilimu owenziwe ngezihloko oqukethe i-glucosamine sulfate, i-chondroitin sulfate, ne-camphor ye-osteoarthritis yamadolo. J Rheumatol 2003; 30: 523-8 .. Buka okungaqondakali.
71. UMay B, Kuntz HD, uKieser M, Kohler S. Ukusebenza kwenhlanganisela kawoyela we-peppermint kawoyela / we-caraway ongaguquki ku-non-ulcer dyspepsia. I-Arzneimittelforschung 1996; 46: 1149-53. Buka okungaqondakali.
72. Anon. I-AEterna imemezela ukuqala kokubhaliswa kweziguli kwesivivinyo somtholampilo esixhaswe isigaba se-NIH se-AE-941 / Neovastat ekwelapheni umdlavuza wamaphaphu. I-Aeterna 2000 News Release 2000 Meyi 17.
73. Sheu JR, Fu CC, Tsai ML, Chung WJ. Umphumela we-U-995, i-angiogenesis inhibitor esuselwa ku-shark cartilage enamandla, kwimisebenzi elwa ne-angiogenesis kanye neye-anti-tumor. I-Anticancer Res 1998; 18: 4435-41. Buka okungaqondakali.
74. UFontenele JB, Viana GS, Xavier-Filho J, de-Alencar JW. Umsebenzi olwa nokuvuvukala kanye ne-analgesic wengxenyenamba encibilikiswa ngamanzi kusuka ku-shark cartilage. I-Braz J Med Biol Res 1996; 29: 643-6. Buka okungaqondakali.
75. UFontenele JB, Araujo GB, de Alencar JW, Viana GS. Imiphumela ye-analgesic ne-anti-inflammatory ye-shark cartilage ingenxa ye-peptide molecule futhi incike ohlelweni lwe-nitric oxide (NO). I-Biol Pharm Bull 1997; 20: 1151-4. Buka okungaqondakali.
76. I-Gomes EM, i-Souto PR, i-Felzenszwalb I. I-Shark-cartilage equkethe ukulungiselela ivikela amaseli ekulweni nomonakalo we-hydrogen peroxide kanye ne-mutagenesis. IMutat Res 1996; 367: 204-8. Buka okungaqondakali.
77. UMathews J. Abezindaba baphakela ukuqubuka ngoqwanga lukashaka njengokwelapha umdlavuza. UJ Natl Cancer Inst 1993; 85: 1190-1. Buka okungaqondakali.
78. UBhargava P, Trocky N, Marshall J, et al. Isigaba I ukuphepha, ukubekezelelana kanye nesifundo se-pharmacokinetic somthamo okhulayo, ukukhuphuka kokufakwa okuqhubekayo kwe-MSI-1256F (iScalamine Lactate) ezigulini ezinomdlavuza osezingeni eliphezulu. I-Proc Am Soc Clinical Oncol 1999; 18: A698.
79. UKalidas M, uHammond LA, uPatnaik P, et al. Isigaba I nesifundo se-pharmacokinetic (PK) se-angiogenesis inhibitor, squalamine lactate (MSI-1256F). I-Proc Am Soc Clinical Oncol 2000; 19: A698.
80. UPatnaik A, uRowinsky E, uHammond L, et al. Isigaba I kanye nesifundo se-pharmacokinetic (PK) se-angiogenesis inhibitor eyingqayizivele, i-squalamine lactate (MSI-1256F). I-Proc Am Soc Clinical Oncol 1999; 18: A622.
81. U-Evans WK, uLatreille J, uBatist G, et al. I-AE-941, i-inhibitor ye-angiogenesis: isizathu sokuthuthuka ngokuhlanganiswa ne-induction chemotherapy / radiotherapy ezigulini ezinomdlavuza ongewona omncane wamaseli wamaphaphu (NSCLC). I-Proc Am Soc Clinical Oncol 1999; 18: A1938.
82. URosenbluth RJ, uJennis AA, uCantwell S, uDeVries J. Oral shark cartilage ekwelapheni iziguli ezinezicubu zobuchopho eziphambili ezithuthukile. Isifundo somshayeli wesigaba II. I-Proc Am Soc Clinical Oncol 1999; 18: A554.
83. ILeitner SP, iRothkopf MM, iHaverstick L, et al. Izifundo ezimbili zesigaba II somlomo owomile we-shark cartilage powder (SCP) ezigulini (pts) ezinesifuba se-metastatic noma umdlavuza we-prostate ophikisayo ekwelashweni okujwayelekile. I-Proc Am Soc Clinical Oncol 1998; 17: A240.
84. I-Natl Cancer Institute CancerNet. I-Cartilage iwebhusayithi: www.cancer.gov (Kufinyelelwe ngo-18 Agasti 2000).
85. I-Berbari P, Thibodeau A, Germain L, et al Imiphumela ye-Antiangiogenic yokuphathwa ngomlomo kwe-liquid cartilage ekhishwe kubantu. UJ Surg Res 1999; 87: 108-13. Buka okungaqondakali.
86. IHillman JD, iPeng AT, iGilliam AC, iRemick SC. Ukwelashwa kweKaposi Sarcoma ngokulawulwa ngomlomo kwe-shark cartilage ku-Human Herpes virus 8-seropositive, Human Immunodeficiency Virus-Seronegative homosexual man. I-Arch Dermatol 2001; 137: 1149-52. Buka okungaqondakali.
87. Izichasiselo zesilingo somtholampilo seNeovastat. Kwethulwe emhlanganweni waminyaka yonke we-American Association for Cancer Research 92. Mashi 27, 2001.
88. UWilson JL. I-topical shark cartilage inqoba i-psoriasis: ukubuyekezwa kocwaningo kanye nemiphumela yokuqala yomtholampilo. I-Altern Complement Ther 2000; 6: 291.
89. UMiller DR, Anderson GT, Stark JJ, et al. Isivivinyo sesiGaba se-I / II sokuphepha nokusebenza koqwanga lukashaka ekwelapheni umdlavuza osezingeni eliphezulu. UJ Clin Oncol 1998; 16: 3649-55. Buka okungaqondakali.
90. ILane IW, iComac L. Sharks awutholi umdlavuza. IGarden City, NY: Iqembu le-Avery Publishing; 1992.
91. Hunt TJ, Connelly JF. Uqwanga lukashaka ekwelashweni komdlavuza. NginguJ J Health Syst Pharm 1995; 52: 1756-60. Buka okungaqondakali.
92. U-Ashar B, u-Vargo E. Shark hepatitis obangelwa uqwanga [incwadi]. U-Ann Intern Med 1996; 125: 780-1. Buka okungaqondakali.

Kugcine ukubuyekezwa - 03/14/2019